Breaking News Instant updates and real-time market news.

2017-12-01 15:00:06

HASI

Hannon Armstrong

$23.75

-0.02 (-0.08%)

15:00

12/01/17

12/01

15:00

12/01/17

15:00

Higher option volume in Hannon Armstrong driven by put buying

Higher option volume in Hannon Armstrong driven by put buying. The stock flat at $23.77 and Mar 22.5 puts trade across the exchanges for $1 when bid-ask was 55c to $1. More than 2.5K trade at that line and the bearish flow will create the largest open interest block in the name. The new positions capture one earnings cycle in February.

Roth Capital analyst Philip Shen sees Hannon Armstrong announced deal to acquire 4k acres of land supporting 690MW of solar for $144M as an incremental positive as it appears to nearly double the company's solar land exposure, which typically has attractive spreads and ROE. The analyst believes shares are currently undervalued and says he would be a buyer at these levels. He reiterates a Buy rating and $25 price target on the stock.

03/13/17

BOFA

03/13/17INITIATIONTarget $22BOFABuy

Hannon Armstrong reinstated with a Buy at BofA/Merrill

BofA/Merrill analyst Brian Chin reinstated Hannon Armstrong with a Buy rating and $22 price target. The analyst believes the recent pullback in the shares, coupled with Hannon's efficiency model, make the name attractive.

AT&T Mobility has reached a tentative agreement with the Communications Workers of America in Mobility Orange contract negotiations. The four-year agreement, which will be submitted to the union's membership for a ratification vote in coming days, covers about 20,000 employees in 36 states and the District of Columbia - AT&T's Mobility Orange unit, which encompasses CWA Districts 1, 2-13, 4, 7 and 9.

Pfizer announced that the United States FDA has approved IXIFI, a chimeric human-murine monoclonal antibody against tumor necrosis factor, as a biosimilar to Remicade for all eligible indications of the reference product. The FDA has approved IXIFI as a treatment for patients with rheumatoid arthritis, Crohn's disease, pediatric Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

Western Alliance Bancorporation announced that during the first quarter of 2018 Robert Sarver will transition from Chairman and CEO to Executive Chairman. In conjunction with Sarver's change in role, Ken Vecchione will be promoted to Chief Executive Officer, Dale Gibbons to Vice Chairman and Chief Financial Officer, and James Haught to President and Chief Operating Officer, all effective April 1, 2018.

Aqua America announced that President and CEO Christopher H. Franklin has been elected chairman of the board, effective Jan. 1, 2018. Franklin became CEO in July 2015 and has served on the board of directors since October 2015. He succeeds Nicholas DeBenedictis, former CEO, who will continue to serve on the board as chairman emeritus.